PTC Inc. (PTC)
PTC to Report Q4 Earnings: Here's What Investors Should Know
PTC's fiscal fourth-quarter performance is likely to have been driven by strong business momentum across PLM and CAD segments amid forex fluctuations.
PTC Inc. (PTC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of PTC Inc. (PTC) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PTC Inc. (PTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will PTC's AWS Partnership to Enhance Onshape Drive Stock Upward?
PTC Inc. PTC has inked a Strategic Collaboration Agreement with Amazon Web Services (“AWS”) to boost the growth of its Onshape solution. This collaboration aims to enhance Onshape's capabilities, promote customer adoption and advance AI initiatives, all intended to help designers and engineers create high-quality products more swiftly and efficiently.
2 Stocks Down 66% and 8% to Buy Right Now
Roblox is posting very strong growth, but its stock still trades far below its previous high. Despite challenging end-market trends, software company PTC keeps generating double-digit growth in its key metric.
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
PTC Therapeutics, Inc. achieved dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients, using 5 mg and 10 mg of PTC518. The global Huntington's Disease treatment market is expected to reach $3.06 billion by 2033. NDA of sepiapterin for the treatment of patients with phenylketonuria submitted July 2024.
PTC Inc. (PTC) Up 0.7% Since Last Earnings Report: Can It Continue?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
1 Magnificent Software Stock Down 10% to Buy and Hold Forever
The annual run rate of recurring revenue continues to grow at a double-digit rate. Free cash flow is growing more than recurring revenue growth.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC Inc. (PTC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC's Q3 Earnings Match Estimates, Revenues Decrease Y/Y
PTC Inc. PTC reported third-quarter fiscal 2024 non-GAAP earnings per share (EPS) of 98 cents, down 1% on a year-over-year basis. The figure came in line with the Zacks Consensus Estimate.
